GDC 0575
Alternative Names: ARRY-575; GDC-0575; RG 7741; RO 6845979Latest Information Update: 02 Oct 2021
Price :
$50 *
At a glance
- Originator Array BioPharma
- Developer Genentech
- Class Antineoplastics; Small molecules
- Mechanism of Action Checkpoint kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lymphoma; Solid tumours
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for phase-I development in Lymphoma(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in France (PO)
- 28 Dec 2019 No recent reports of development identified for phase-I development in Lymphoma(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
- 28 Dec 2019 No recent reports of development identified for phase-I development in Lymphoma(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in France (PO)